Gen RAS trong các khối u não và sự tham gia của microRNA let-7

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635–647. https://doi.org/10.1016/j.cell.2005.01.014

Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67(16):7713–7722. https://doi.org/10.1158/0008-5472.CAN-07-1083

Gilles ME, Slack FJ (2018) Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets 22(11):929–939. https://doi.org/10.1080/14728222.2018.1535594

Degrauwe N, Schlumpf TB, Janiszewska M, Martin P, Cauderay A, Provero P, Riggi N, Suvà ML, Paro R, Stamenkovic I (2016) The RNA binding protein IMP2 preserves glioblastoma stem cells by preventing let-7 target gene silencing. Cell Rep 15(8):1634–1647. https://doi.org/10.1016/j.celrep.2016.04.086

Li Y, Zhang X, Chen D, Ma C (2016) Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2. Tumour Biol 37(6):8107–8119. https://doi.org/10.1007/s13277-015-4674-6

Song H, Zhang Y, Liu N, Zhang D, Wan C, Zhao S, Kong Y, Yuan L (2016) Let-7b inhibits the malignant behavior of glioma cells and glioma stem-like cells via downregulation of E2F2. J Physiol Biochem. https://doi.org/10.1007/s13105-016-0512-6

Wang XR, Luo H, Li HL, Cao L, Wang XF, Yan W, Wang YY, Zhang JX, Jiang T, Kang CS, Liu N, You YP, Chinese Glioma Cooperative Group (CGCG) (2013) Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro Oncol 15(11):1491–1501. https://doi.org/10.1093/neuonc/not107

Buonfiglioli A, Efe IE, Guneykaya D, Ivanov A, Huang Y, Orlowski E, Krüger C, Deisz RA, Markovic D, Flüh C, Newman AG, Schneider UC, Beule D, Wolf SA, Dzaye O, Gutmann DH, Semtner M, Kettenmann H, Lehnardt S (2019) let-7 microRNAs regulate microglial function and suppress glioma growth through toll-like receptor 7. Cell Rep 29(11):3460–3471. https://doi.org/10.1016/j.celrep.2019.11.029

Huang Y, Liu P, Luo J, Zhu C, Lu C, Zhao N, Zhao W, Cui W, Yang X (2023) Par6 enhances glioma invasion by activating MEK/ERK pathway through a LIN28/let-7d positive feedback loop. Mol Neurobiol 60(3):1626–1644. https://doi.org/10.1007/s12035-022-03171-0

Lee ST, Chu K, Oh HJ, Im WS, Lim JY, Kim SK, Park CK, Jung KH, Lee SK, Kim M, Roh JK (2011) Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 102(1):19–24. https://doi.org/10.1007/s11060-010-0286-6

Wang X, Xin Z, Xu Y, Ma J (2016) Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma. Tumour Biol 37(5):5963–5970. https://doi.org/10.1007/s13277-015-4455-2

Wang Z, Lin S, Zhang J, Xu Z, Xiang Y, Yao H, Ge L, Xie D, Kung HF, Lu G et al (2016) Loss of MYC and E-box3 binding contributes to defective MYC-mediated transcriptional suppression of human MC-let-7a- 1$let-7d in glioblastoma. Oncotarget 7:56266–56278. https://doi.org/10.18632/oncotarget.10517

Xie C, Chen W, Zhang M, Cai Q, Xu W, Li X, Jiang S (2015) MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells. FEBS Lett 589(15):1958–1965. https://doi.org/10.1016/j.febslet.2015.05.030

Li Y, Li Y, Ge P, Ma C (2017) Mir-126 regulates the ERK pathway via targeting KRAS to inhibit the glioma cell proliferation and invasion. Mol Neurobiol 54(1):137–145. https://doi.org/10.1007/s12035-015-9654-8

Yu ML, Wang JF, Wang GK, You XH, Zhao XX, Jing Q, Qin YW (2011) Vascular smooth muscel cell proliferation is influenced by let-7d microRNA and its interaction with KRAS. Circ J 75:703–709. https://doi.org/10.1253/circj.cj-10-0393

Zhao Y, Pang D, Wang C, Zhong S, Wang S (2016) MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway. Tumour Biol 37(8):11485–11493. https://doi.org/10.1007/s13277-016-5027-9

Wang L, Shi ZM, Jiang CF, Liu X, Chen QD, Qian X, Li DM, Ge X, Wang XF, Liu LZ, You YP, Liu N, Jiang BH (2014) MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget 5(14):5416–5427. https://doi.org/10.18632/oncotarget.2116

Shi Z, Chen Q, Li C, Wang L, Qian X, Jiang C, Liu X, Wang X, Li H, Kang C, Jiang T, Liu LZ, You Y et al (2014) MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro Oncol 16:1341–1353. https://doi.org/10.1093/neuonc/nou084

Chaudhry MA, Sachdeva H, Omaruddin RA (2010) Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol 29(9):553–561. https://doi.org/10.1089/dna.2009.0978

Evers L, Schäfer A, Pini R, Zhao K, Stei S, Nimsky C, Bartsch JW (2023) Identification of dysregulated microRNAs in glioblastoma stem-like cells. Brain Sci 13(2):350. https://doi.org/10.3390/brainsci13020350

Guo Y, Yan K, Fang J, Qu Q, Zhou M, Chen F (2013) Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res 32(1):41. https://doi.org/10.1186/1756-9966-32-41

Mao XG, Hütt-Cabezas M, Orr BA, Weingart M, Taylor I, Rajan AK, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G et al (2013) LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget 4:1050–1064. https://doi.org/10.18632/oncotarget.1131

Gunzburg MJ, Sivakumaran A, Pendini NR, Yoon JH, Gorospe M, Wilce MC, Wilce JA (2015) Cooperative interplay of let-7 mimic and HuR with MYC RNA. Cell Cycle 14(17):2729–2733. https://doi.org/10.1080/15384101.2015.1069930

He XY, Chen JX, Zhang Z, Li CL, Peng QL, Peng HM (2010) The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol 136(7):1023–1028

Maldotti M, Incarnato D, Neri F, Krepelova A, Rapelli S, Anselmi F, Parlato C, Basile G, Dettori D, Calogero R, Oliviero S (2016) The long intergenic non-coding RNA CCR492 functions as a let-7 competitive endogenous RNA to regulate c-Myc expression. Biochim Biophys Acta 1859(10):1322–1332. https://doi.org/10.1016/j.bbagrm.2016.06.010

Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ (2007) MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67(20):9762–9770. https://doi.org/10.1158/0008-5472.CAN-07-2462

Wong TS, Man OY, Tsang CM, Tsao SW, Tsang RK, Chan JY, Ho WK, Wei WI, To VS (2011) MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol 137(3):415–422. https://doi.org/10.1007/s00432-010-0898-4

Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sültmann H, Lyko F (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67(4):1419–1423. https://doi.org/10.1158/0008-5472.CAN-06-4074

Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T (2007) The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 282(11):8256–8264. https://doi.org/10.1074/jbc.M607712200

Zhou Q, Frost RJA, Anderson C, Zhao F, Ma J, Yu B, Wang S (2017) let-7 contributes to diabetic retinopathy but represses pathological ocular angiogenesis. Mol Cell Biol 37(16):00001–00017. https://doi.org/10.1128/MCB.00001-17

Frost RJ, Olson EN (2011) Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci USA 108(52):21075–21080. https://doi.org/10.1073/pnas.1118922109

Shui B, La Rocca G, Ventura A, Haigis KM (2022) Interplay between K-RAS and miRNAs. Trends Cancer 8(5):384–396. https://doi.org/10.1016/j.trecan.2022.01.002

Danac JMC, Garcia RL (2021) CircPVT1 attenuates negative regulation of NRAS by let-7 and drives cancer cells towards oncogenicity. Sci Rep 11(1):9021. https://doi.org/10.1038/s41598-021-88539-3

Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN (2010) Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 18(3):282–293. https://doi.org/10.1016/j.ccr.2010.08.013

Sharma V, Dixit D, Koul N, Mehta VS, Sen E (2011) Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma. J Mol Med 89(2):123–136. https://doi.org/10.1007/s00109-010-0683-5

Stainthorp AK, Lin CC, Wang D, Medhi R, Ahmed Z, Suen KM, Miska EA, Whitehouse A, Ladbury JE (2023) Regulation of microRNA expression by the adaptor protein GRB2. Sci Rep 13(1):9784. https://doi.org/10.1038/s41598-023-36996-3

Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL (2013) MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Mol Cell Biol 33(11):2260–2274. https://doi.org/10.1128/MCB.00269-13

Asl ER, Amini M, Najafi S, Mansoori B, Mokhtarzadeh A, Mohammadi A, Lotfinejad P, Bagheri M, Shirjang S, Lotfi Z, Rasmi Y, Baradaran B (2021) Interplay between MAPK/ERK signaling pathway and MicroRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci 278:119499. https://doi.org/10.1016/j.lfs.2021.119499

Masliah-Planchon J, Garinet S, Pasmant E (2016) RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget 7(25):38892–38907. https://doi.org/10.18632/oncotarget.6476.Review

Jinesh G, Sambandam V, Vijayaraghavan S et al (2018) Molecular genetics and cellular events of K-Ras-driven tumorigenesis. Oncogene 37:839–846. https://doi.org/10.1038/onc.2017.377

Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7(6):759–764. https://doi.org/10.4161/cc.7.6.5834

Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105(10):3903–3908. https://doi.org/10.1073/pnas.0712321105

Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ (2010) Regression of murine lung tumors by the let-7 microRNA. Oncogene. 29(11):1580–7. https://doi.org/10.1038/onc.2009.445

Chirshev E, Oberg KC, Ioffe YJ, Unternaehrer JJ (2019) Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. Clin Transl Med 8(1):24. https://doi.org/10.1186/s40169-019-0240-y

Ma L, Li GZ, Wu ZS, Meng G (2014) Prognostic significance of let-7b expression in breast cancer and correlation to its target gene of BSG expression. Med Oncol 31(1):773. https://doi.org/10.1007/s12032-013-0773-7

Petrillo M, Zannoni GF, Beltrame L, Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L, Vizzielli G, Scambia G, D’Incalci M, Romualdi C, Marchini S (2016) Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Ann Oncol 27(4):625–634. https://doi.org/10.1093/annonc/mdw007

Yu F et al (2007) let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 131:1109–1123. https://doi.org/10.1016/j.cell.2007.10.054

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106

Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E, Chang SM, Nabors LB, Ahluwalia MS, Stupp R, Mehta MP, Reardon DA, Grossman SA, Sulman EP, Sampson JH, Khagi S, Weller M, Cloughesy TF, Wen PY, Khasraw M (2022) Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin Cancer Res 28(4):594–602. https://doi.org/10.1158/1078-0432.CCR-21-2750

Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA. 310(17):1842–50. https://doi.org/10.1001/jama.2013.280319

Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10(5):319–331. https://doi.org/10.1038/nrc2818

Thomas AA, Brennan CW, DeAngelis LM, Omuro AM (2014) Emerging therapies for glioblastoma. JAMA Neurol 71(11):1437–1444. https://doi.org/10.1001/jamaneurol.2014.1701

Yang K, Wu Z, Zhang H et al (2022) Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21:39. https://doi.org/10.1186/s12943-022-01513-z

Khosla D (2016) Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med 4(3):54. https://doi.org/10.3978/j.issn.2305-5839.2016.01.25

Behnan J, Finocchiaro G, Hanna G (2019) The landscape of the mesenchymal signature in brain tumours. Brain 142(4):847–866. https://doi.org/10.1093/brain/awz044

Blomquist MR, Ensign SF, D’Angelo F, Phillips JJ, Ceccarelli M, Peng S et al (2020) Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. Neurooncol Adv 2(1):vdaa078. https://doi.org/10.1093/noajnl/vdaa078

Büssing I, Slack FJ, Grosshans H (2008) Let-7 microRNAs in development stem cells and cancer. Trends Mol Med 14:400–409. https://doi.org/10.1016/j.molmed.2008.07.001

Khodayari N, Mohammed KA, Goldberg EP, Nasreen N (2011) EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther 18(11):806–816. https://doi.org/10.1038/cgt.2011.50

Ahir BK, Ozer H, Engelhard HH, Lakka SS (2017) MicroRNAs in glioblastoma pathogenesis and therapy: a comprehensive review. Crit Rev Oncol Hematol 120:22–33. https://doi.org/10.1016/j.critrevonc.2017.10.003

Chen M, Medarova Z, Moore A (2021) Role of microRNAs in glioblastoma. Oncotarget 12(17):1707–1723. https://doi.org/10.18632/oncotarget.28039

Zhang W, Zhao W, Ge C, Li X, Yang X, Xiang Y, Sun Z (2019) Decreased let-7b is associated with poor prognosis in glioma. Medicine 98(22):e15784. https://doi.org/10.1097/MD.0000000000015784

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L (2013) TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 155(2):462–77. https://doi.org/10.1016/j.cell.2013.09.034

Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L (2012) Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS ONE 7(9):e44399. https://doi.org/10.1371/journal.pone.0044399

Tanno B, Babini G, Leonardi S, Giardullo P, De Stefano I, Pasquali E, Ottolenghi A, Atkinson MJ, Saran A, Mancuso M (2016) Ex vivo miRNome analysis in Ptch1+/ cerebellum granule cells reveals a subset of miRNAs involved in radiation-induced medulloblastoma. Oncotarget. https://doi.org/10.18632/oncotarget.11938

Turner JD, Williamson R, Almefty KK, Nakaji P, Porter R, Tse V, Kalani MY (2010) The many roles of microRNAs in brain tumor biology. Neurosurg Focus. 28(1):E3. https://doi.org/10.3171/2009.10.FOCUS09207

Shahab SW, Roggeveen CM, Sun J, Kunhiraman H, McSwain LF, Juraschka K, Kumar SA, Saulnier O, Taylor MD, Schniederjan M, Schnepp RW, MacDonald TJ, Kenney AM (2023) The LIN28B-let-7-PBK pathway is essential for group 3 medulloblastoma tumor growth and survival. Mol Oncol. https://doi.org/10.1002/1878-0261.13477

Westphal MS, Lee E, Schadt EE, Sholler GS, Zhu J (2022) Identification of Let-7 miRNA activity as a prognostic biomarker of SHH medulloblastoma. Cancers 14:139. https://doi.org/10.3390/cancers14010139

Knowles T, Huang T, Qi J, An S, Burket N, Cooper S, Nazarian J, Saratsis AM (2023) LIN28B and Let-7 in diffuse midline glioma: a review. Cancers 15(12):3241. https://doi.org/10.3390/cancers15123241

Koncar RF, Dey BR, Stanton AJ, Agrawal N, Wassell ML, McCarl LH, Locke AL, Sanders L, Morozova-Vaske O, Myers MI, Hamilton RL, Carcaboso AM, Kohanbash G, Hu B, Amankulor NM, Felker J, Kambhampati M, Nazarian J, Becher OJ, James CD, Hashizume R, Broniscer A, Pollack IF, Agnihotri S (2019) Identification of novel RAS signaling therapeutic vulnerabilities in diffuse intrinsic pontine gliomas. Cancer Res 79(16):4026–4041. https://doi.org/10.1158/0008-5472.CAN-18-3521

Lo HW (2010) Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets. 10(8):840–8

Gilbertson RJ, Langdon JA, Hollander A, Hernan R, Hogg TL, Gajjar A, Fuller C, Clifford SC (2006) Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer 42(5):646–649. https://doi.org/10.1016/j.ejca.2005.11.023

Mukhopadhyay S, Vander Heiden MG, McCormick F (2021) The metabolic landscape of RAS-driven cancers from biology to therapy. Nat Cancer 2(3):271–283. https://doi.org/10.1038/s43018-021-00184-x

Milinkovic VP, Skender Gazibara MK, Manojlovic Gacic EM, Gazibara TM, Tanic NT (2014) The impact of TP53 and RAS mutations on cerebellar glioblastomas. Exp Mol Pathol. 97(2):202–7. https://doi.org/10.1016/j.yexmp.2014.07.009

Eleveld TF et al (2015) Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 47(8):864–71

Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann DH, Squire JA, Nagy A, Guha A (2001) Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61(9):3826–3836

Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108(6):467–470

Vitucci M, Karpinich NO, Bash RE, Werneke AM, Schmid RS, White KK, McNeill RS, Huff B, Wang S, Van Dyke T, Miller CR (2013) Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro Oncol 15(10):1317–1329. https://doi.org/10.1093/neuonc/not084

Dasgupta B, Li W, Perry A, Gutmann DH (2005) Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 65(1):236–245.

Holmen SL, Williams BO (2005) Essential role for Ras signaling in glioblastoma maintenance. Cancer Res 65(18):8250–8255. https://doi.org/10.1158/0008-5472.CAN-05-1173

Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y, Raught B, Zhang ZY, Zadeh G, Ohh M (2015) Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun 6:8859. https://doi.org/10.1038/ncomms9859

Gömöri E, Dóczi T, Pajor L, Matolcsy A (1999) Sporadic p53 mutations and absence of ras mutations in glioblastomas. Acta Neurochir 141(6):593–599. https://doi.org/10.1007/s007010050348

Masliah-Planchon J, Garinet S, Pasmant E (2016) RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 7(25):38892–38907. https://doi.org/10.18632/oncotarget.6476(Review)

Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, Ligon KL, Kesari S, Esau C, Stephens RM et al (2011) Human glioma growth is controlled by microRNA-10b. Cancer Res 71(10):3563–3572. https://doi.org/10.1158/0008-5472.CAN-10-3568

Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, Raychaudhury A, Newton HB, Chiocca EA, Lawler S (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68(22):9125–9130. https://doi.org/10.1158/0008-5472.CAN-08-2629

Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 107:2183–2188. https://doi.org/10.1158/0008-5472.CAN-08-2629

Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by microRNAs. Cancer Res 71:3387–3399. https://doi.org/10.1073/pnas.0909896107

Kwak HJ, Kim YJ, Chun KR, Woo YM, Park SJ, Jeong JA, Jo SH, Kim TH, Min HS, Chae JS, Choi EJ, Kim G, Shin SH, Gwak HS, Kim SK, Hong EK, Lee GK, Choi KH, Kim JH, Yoo H, Park JB, Lee SH (2011) Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 30(21):2433–2442. https://doi.org/10.1038/onc.2010.620

Hydbring P, Badalian-Very G (2013) Clinical applications of microRNAs. F1000Res 2:136. https://doi.org/10.12688/f1000research.2-136.v3

Diener C, Keller A, Meese E (2022) Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet 38(6):613–626. https://doi.org/10.1016/j.tig.2022.02.006

Segal M, Biscans A, Gilles ME, Anastasiadou E, De Luca R, Lim J, Khvorova A, Slack FJ (2020) Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 in vivo. Mol Ther Nucleic Acids 19:267–277. https://doi.org/10.1016/j.omtn.2019.11.008

Segal M, Slack FJ (2020) Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opin Drug Discov 15(9):987–992. https://doi.org/10.1080/17460441.2020.1765770

Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, Trivedi P, Escolar DM, Jackson AL, Slack FJ (2021) Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo. Clin Cancer Res 27(4):1139–1149. https://doi.org/10.1158/1078-0432.CCR-20-3139

Chakraborty C, Sharma AR, Sharma G, Lee S-S (2021) Therapeutic advances of miRNAs: a preclinical and clinical update. J Adv Res 28:127–138. https://doi.org/10.1016/j.jare.2020.08.012

Romano G, Acunzo M, Nana-Sinkam P (2021) microRNAs as Novel Therapeutics in Cancer. Cancers (Basel). 13(7):1526. https://doi.org/10.3390/cancers13071526

Liang L, He X (2021) A narrative review of microRNA therapeutics: understanding the future of microRNA research. Precis Cancer Med 4:33. https://doi.org/10.21037/pcm-21-28

Kim T, Croce CM (2023) MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med. https://doi.org/10.1038/s12276-023-01050-9

Teplyuk NM, Uhlmann EJ, Gabriely G, Volfovsky N, Wang Y, Teng J, Karmali P, Marcusson E, Peter M, Mohan A, Kraytsberg Y, Cialic R, Chiocca EA, Godlewski J, Tannous B, Krichevsky AM (2016) Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med 8(3):268–287. https://doi.org/10.15252/emmm.201505495

Stalnecker CA, Der CJ (2023) KRAS regulation of miRNA: stepping on the brake to go faster. Mol Cell 83(14):2390–2392. https://doi.org/10.1016/j.molcel.2023.06.029

Helwak A, Kudla G, Dudnakova T, Tollervey D (2013) Mapping the human miRNA interactome by CLASH revealsfrequent noncanonical binding. Cell. 153(3):654–65. https://doi.org/10.1016/j.cell.2013.03.043

Diener C, Keller A, Meese E (2023) The miRNA-target interactions: an underestimated intricacy. Nucleic Acids Res. https://doi.org/10.1093/nar/gkad1142